Literature DB >> 11799394

Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.

J Carpten1, N Nupponen, S Isaacs, R Sood, C Robbins, J Xu, M Faruque, T Moses, C Ewing, E Gillanders, P Hu, P Bujnovszky, I Makalowska, A Baffoe-Bonnie, D Faith, J Smith, D Stephan, K Wiley, M Brownstein, D Gildea, B Kelly, R Jenkins, G Hostetter, M Matikainen, J Schleutker, K Klinger, T Connors, Y Xiang, Z Wang, A De Marzo, N Papadopoulos, O-P Kallioniemi, R Burk, D Meyers, H Grönberg, P Meltzer, R Silverman, J Bailey-Wilson, P Walsh, W Isaacs, J Trent.   

Abstract

Although prostate cancer is the most common non-cutaneous malignancy diagnosed in men in the United States, little is known about inherited factors that influence its genetic predisposition. Here we report that germline mutations in the gene encoding 2'-5'-oligoadenylate(2-5A)-dependent RNase L (RNASEL) segregate in prostate cancer families that show linkage to the HPC1 (hereditary prostate cancer 1) region at 1q24-25 (ref. 9). We identified RNASEL by a positional cloning/candidate gene method, and show that a nonsense mutation and a mutation in an initiation codon of RNASEL segregate independently in two HPC1-linked families. Inactive RNASEL alleles are present at a low frequency in the general population. RNASEL regulates cell proliferation and apoptosis through the interferon-regulated 2-5A pathway and has been suggested to be a candidate tumor suppressor gene. We found that microdissected tumors with a germline mutation showed loss of heterozygosity and loss of RNase L protein, and that RNASEL activity was reduced in lymphoblasts from heterozyogous individuals compared with family members who were homozygous with respect to the wildtype allele. Thus, germline mutations in RNASEL may be of diagnostic value, and the 2-5A pathway might provide opportunities for developing therapies for those with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799394     DOI: 10.1038/ng823

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  152 in total

1.  Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.

Authors:  Annika Rökman; Tarja Ikonen; Eija H Seppälä; Nina Nupponen; Ville Autio; Nina Mononen; Joan Bailey-Wilson; Jeffrey Trent; John Carpten; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Olli-P Kallioniemi; Johanna Schleutker
Journal:  Am J Hum Genet       Date:  2002-04-08       Impact factor: 11.025

2.  Caution on pedigree haplotype inference with software that assumes linkage equilibrium.

Authors:  Daniel J Schaid; Shannon K McDonnell; Liang Wang; Julie M Cunningham; Stephen N Thibodeau
Journal:  Am J Hum Genet       Date:  2002-10       Impact factor: 11.025

3.  Genomewide linkage analysis of familial prostate cancer in the Japanese population.

Authors:  Hiroshi Matsui; Kazuhiro Suzuki; Nobuaki Ohtake; Seiji Nakata; Toshiyuki Takeuchi; Hidetoshi Yamanaka; Ituro Inoue
Journal:  J Hum Genet       Date:  2003-12-10       Impact factor: 3.172

Review 4.  Krüppel cripples prostate cancer: KLF6 progress and prospects.

Authors:  Goutham Narla; Scott L Friedman; John A Martignetti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

5.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.

Authors:  Danielle M Friedrichsen; Janet L Stanford; Sarah D Isaacs; Marta Janer; Bao-Li Chang; Kerry Deutsch; Elizabeth Gillanders; Suzanne Kolb; Katherine E Wiley; Michael D Badzioch; S Lilly Zheng; Patrick C Walsh; Gail P Jarvik; Leroy Hood; Jeffrey M Trent; William B Isaacs; Elaine A Ostrander; Jianfeng Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

Review 6.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

7.  A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.

Authors:  R A Kittles; A B Baffoe-Bonnie; T Y Moses; C M Robbins; C Ahaghotu; P Huusko; C Pettaway; S Vijayakumar; J Bennett; G Hoke; T Mason; S Weinrich; J M Trent; F S Collins; S Mousses; J Bailey-Wilson; P Furbert-Harris; G Dunston; I J Powell; J D Carpten
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

8.  A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.

Authors:  Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

9.  PALB2 variants in hereditary and unselected Finnish prostate cancer cases.

Authors:  Sanna Pakkanen; Tiina Wahlfors; Sanna Siltanen; Mimmi Patrikainen; Mika P Matikainen; Teuvo L J Tammela; Johanna Schleutker
Journal:  J Negat Results Biomed       Date:  2009-12-15

10.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.